Breaking News
Sort by:
Top Post
Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and […]
Nona Biosciences Enters into Antibody Discovery Agreement with OPKO Health's ModeX Therapeutics
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation […]
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
Sangamo Therapeutics, a genomic medicine company, today announced that the United States Food and Drug […]
HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics
Shanghai Stock Exchange-listed company HitGen announced today that it has entered into a research agreement […]
Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and […]
Health Canada Accepts New Drug Submission for lecanemab as Treatment for Early Alzheimer's Disease
BioArctic AB’s partner Eisai announced today that Health Canada has accepted a New Drug Submission […]
CHARM Therapeutics Receives Investment for Deep Learning-Enabled Drug Discovery Research from NVIDIA
CHARM Therapeutics, a 3D deep-learning biotechnology company discovering and developing transformational medicines, today announced an […]
Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma
Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the […]
Sarepta Therapeutics Announces Positive Vote from FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, today announced that the […]
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
LaNova Medicines has announced it has entered into an exclusive license agreement with AstraZeneca, for […]
Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease
Otsuka Pharmaceutical and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the supplemental New […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more